Every 10-Q that Iovance Biotherapeutics, Inc. (IOVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IOVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IOVA filings page.
Iovance Biotherapeutics, Inc. reported Q2 2026 revenue of $99,313 (in thousands), compared with $59,952 a year earlier, driven by Amtagvi at $90,721 and Proleukin at $8,592 (each in thousands). First-half 2026 revenue was $170,743 versus $109,276 (in thousands).
Total Q2 costs and expenses were $151,218 (in thousands) versus $173,726, producing a loss from operations of $51,905 and a net loss of $47,315, or $0.11 per share, compared with a Q2 2025 net loss of $111,658, or $0.33 per share.
As of June 30, 2026, cash, cash equivalents, short-term investments and restricted cash totaled $303.7 million, and net cash used in operating activities for the first half was $132,915 (in thousands). The company raised $148,081 (in thousands) from common stock sales and believes existing capital will fund planned operations for at least twelve months. Amtagvi has approvals in the U.S., Canada and Australia, with additional marketing applications under review, while registrational trials continue in frontline advanced melanoma, previously treated advanced non-small cell lung cancer and select sarcomas.
Iovance Biotherapeutics reported Q1 2026 net product revenue of $71.4 million, primarily from its TIL therapy Amtagvi and IL‑2 product Proleukin, up from $49.3 million a year earlier. Amtagvi contributed $60.2 million and Proleukin $11.2 million.
The company posted a net loss of $79.0 million, improved from a $116.2 million loss in Q1 2025, as operating expenses and stock-based compensation declined. Cash, cash equivalents, short‑term investments and restricted cash totaled $319.4 million, and management believes this is sufficient to fund planned operations for at least the next twelve months while it continues commercial expansion and late‑stage trials in melanoma and other solid tumors.
Iovance Biotherapeutics filed its Q3 2025 10‑Q, reporting total revenue of $67.455 million and a net loss of $91.253 million. Year to date, revenue reached $176.731 million as Amtagvi and Proleukin sales scaled.
Operating costs remained heavy: cost of sales $38.477 million, R&D $75.174 million, SG&A $34.555 million, plus $5.143 million in restructuring charges, driving a loss from operations of $94.901 million. Cash used in operations for the first nine months was $249.843 million.
Liquidity was supported by $306.8 million in cash, cash equivalents, short‑term investments, and restricted cash as of September 30, 2025, and the company states it has sufficient capital to fund planned operations for at least the next twelve months. Shares outstanding were 396,967,970 as of October 15, 2025.